Dimension Therapeutics

This is a key moment in time, says Annalisa Jenkins, executive chair of Silence Therapeutics PLC , for both the company and the interfering RNA (RNAi) space, likening it to the development of antibod

Financings Third-quarter 2017 biopharma financing reached $12.5 billion, just a 6% decrease from the previous quarter's $13.4 billion. ( See Exhibit 1. ) The most money was raised in the follow-on pub

Alcon Pharmaceuticals Ltd. Japan, a Novartis AG subsidiary, has appointed Shoichiro Ogawa as its new president. Ogawa was special counsel and head, commercial excellence, at Abbott Japan Co.

Top Alliance: Halozyme's Very Good Month Bristol-Myers Squibb Co. will pay $105 million up front and as much as $1.76 billion in milestones to use Halozyme Therapeutics Inc. 's Enhanz e techno